Phillip Md Et Al Frost Acquires 280,183 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock in a transaction that occurred on Friday, November 8th. The shares were acquired at an average price of $1.50 per share, with a total value of $420,274.50. Following the completion of the acquisition, the chief executive officer now directly owns 211,512,405 shares of the company’s stock, valued at $317,268,607.50. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

OPKO Health Stock Performance

OPK opened at $1.52 on Monday. The stock has a 50-day moving average of $1.52 and a 200-day moving average of $1.42. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.36 and a current ratio of 1.63. OPKO Health, Inc. has a 52-week low of $0.85 and a 52-week high of $1.75. The company has a market cap of $1.06 billion, a PE ratio of -4.61 and a beta of 1.65.

Analysts Set New Price Targets

A number of research firms have commented on OPK. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Thursday, September 26th. StockNews.com raised shares of OPKO Health to a “sell” rating in a research note on Saturday, July 27th. Piper Sandler restated an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th. Finally, Barrington Research reiterated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a report on Friday.

Hedge Funds Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC boosted its holdings in shares of OPKO Health by 5.9% during the 1st quarter. Commonwealth Equity Services LLC now owns 437,276 shares of the biotechnology company’s stock worth $525,000 after buying an additional 24,350 shares during the period. BNP Paribas Financial Markets grew its position in shares of OPKO Health by 23.7% in the first quarter. BNP Paribas Financial Markets now owns 336,315 shares of the biotechnology company’s stock valued at $404,000 after purchasing an additional 64,443 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of OPKO Health in the first quarter worth about $47,000. Lazard Asset Management LLC acquired a new position in shares of OPKO Health during the 1st quarter worth about $258,000. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of OPKO Health by 4.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock worth $536,000 after purchasing an additional 17,671 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.